Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.7.4215

Clinical Significance and Prognostic Value of Pentraxin-3 as Serologic Biomarker for Lung Cancer  

Zhang, Dai (Department of Clinical Laboratory, the First Affiliated Hospital of Henan University of Traditional Chinese Medicine)
Ren, Wei-Hong (Department of Clinical Laboratory, the First Affiliated Hospital of Henan University of Traditional Chinese Medicine)
Gao, Yun (Center of Clinical Laboratory, Henan Province Tumour Hospital)
Wang, Nian-Yue (Department of Clinical Laboratory, the Second Affiliated Hospital of Southeast University)
Wu, Wen-Jun (Department of Clinical Laboratory, the First Affiliated Hospital of Henan University of Traditional Chinese Medicine)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.7, 2013 , pp. 4215-4221 More about this Journal
Abstract
Purposes: Lung cancer is prevalent worldwide and improvements in timely and effective diagnosis are need. Pentraxin-3 as a novel serum marker for lung cancer (LC) has not been validated in large cohort studies. The aim of the study was to assess its clinical value in diagnosis and prognosis. Methods: We analyzed serum PTX-3 levels in a total of 1,605 patients with LC, benign lung diseases and healthy controls, as well as 493 non-lung cancer patients including 12 different types of cancers. Preoperative and postoperative data were further assessed in patients undergoing LC resection. The diagnostic performance of PTX-3 for LC and early-stage LC was assessed using receiver operating characteristics (ROC) by comparing with serum carcinoembryonic antigen (CEA), cytokeratin 19 fragments (CYFRA 21-1). Results: Levels of PTX-3 in serum were significantly higher in patients with LC than all controls. ROC curves showed the optimum diagnostic cutoff was 8.03ng/mL (AUC 0.823, [95%CI 0.789-0.856], sensitivity 72.8%, and specificity 77.3% in the test cohort; 0.802, [95%CI 0.762-0.843], sensitivity 69.7%, and specificity 76.4% in the validate cohort). Similar diagnostic performance of PTX-3 was observed for early-stage LC. PTX-3 decreased following surgical resection of LC and increased with tumor recurrence. Significantly elevated PTX-3 levels were also seen in patients with non-lung cancers. Conclusions: The present data revealed that PTX-3 was significantly increased in both tissue and serum samples in LC patients. PTX-3 is a valuable biomarker for LC and improved identification of patients with LC and early-stage LC from those with non-malignant lung diseases.
Keywords
Lung neoplasm; serum marker; pentraxin-3; diagnosis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Alessandro R, Fontana S, Kohn E, De Leo G (2005). Proteomic strategies and their application in cancer research. Tumori, 9, 447-55.
2 Allin KH, Bojesen SE, Nordestgaard BG (2009). Baseline C-Reactive Protein Is Associated With Incident Cancer and Survival in Patients With Cancer. J Clin Oncol, 27, 2217-24.   DOI   ScienceOn
3 Balkwill F, Mantovani A (2001). Inflammation and cancer: back to Virchow? Lancet, 357, 539-45   DOI   ScienceOn
4 Banks R, Selby P (2003). Clinical proteomics-insights into pathologies and benefits for patients. Lancet, 362, 415-6.   DOI   ScienceOn
5 Deban L, Jaillon S, Garlanda C, et al (2010). Pentraxins in innate immunity: lessons from PTX3. Cell Tissue Res, 343, 237-49.
6 Diamandis EP, Goodglick L, Planque C, et al (2011). Pentraxin-3 is a novel biomarker of lung Carcinoma. Clin Cancer Res, 17, 2395-99.   DOI
7 Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.   DOI   ScienceOn
8 Garlanda C, Bottazzi B, Bastone A, et al (2005). Pentraxins at the crossroads between innate mmunity,inflammation, matrix deposition, and female fertility. Annu Rev Immunol, 23, 337-66.   DOI   ScienceOn
9 Groome PA, Bolejack V, Cruwley JJ, et a1 (2007).The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol, 2, 694-705.   DOI
10 Hassanein M, Callison JC, Callaway-Lane C, et al (2012). The state of molecular biomarkers for the early detection of lung cancer. Cancer Prev Res, 5, 992-1006.   DOI
11 IARC Working Group (1997). IARC handbook of cancer prevention, volume 1: non-steroidal anti-inflammatory drugs. Lyon (France): IARC-WHO.
12 Jackson JR, Seed MP, Kircher CH, et al (1997). The codependence of angiogenesis and chronic inflammation. FASEB J, 11, 457-65.
13 Jaiswal M, LaRusso NF, Burgart LJ, et al (2000). Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res, 60, 184-90.
14 Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.   DOI
15 Keller A, Leidinger P, Gislefoss R, et a1(201l). STable serum miRNA profiles as potential tool for non-invasive lung cancer diagnosis. RNA Biol, 8, 506-16.   DOI
16 Kulasingam V, Diamandis EP (2008). Strategies for discovering novelcancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol, 5, 588-99.   DOI   ScienceOn
17 Kuper H, Adami HO, Trichopoulos D (2000). Infections as a major prevenTable cause of human cancer. J Intern Med, 248, 171-83.   DOI   ScienceOn
18 Coussens LM, Werb Z (2002). Inflammation and cancer. Nature, 19, 860-67
19 Locker GY, Hamilton S, Harris J, et al (2006). ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol, 24, 5313-27.   DOI   ScienceOn
20 Locatelli M, Ferrero S, Martinelli Boneschi F, et al.The long pentraxin PTX3 as a correlate of cancer-related inflammation and prognosis of malignancy in gliomas(2013). J Neuroimmunol, 260, 99-106
21 Martini N,Baills MS, Burt ME, et a1(1995). Incidence of local recurrence and second primaries in resected stage I lung cancer. J Thorac Cardiovasc Surg, 109, 120-9.   DOI   ScienceOn
22 McWilliams A, Lmn B, Sutedja T (2009). Early proximal lung cancer diagnosis and treatment. Eur Respir J, 33, 656-65.   DOI   ScienceOn
23 Okutani D (2006). The role of long pentraxin 3, a new inflammatory mediator in inflammatory responses. Nihon Rinsho Meneki Gakkai Kaishi, 29, 107-13.   DOI   ScienceOn
24 Pepe MS, Etzioni R, Feng Z, et al (2001). Phases of biomarker development for early detection of cancer. J Natl Cancer Inst, 93, 1054-61.   DOI   ScienceOn
25 Planque C, Kulasingam V, Smith CR, et al (2009). Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines. Mol Cell Proteomics, 8, 2746-58.   DOI   ScienceOn
26 Pujol JL, Grenier J, Daures JP, et al (1993). Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res, 53, 61-6.
27 Rabman SM, Gonzalez AL, Li M, et a1 (2011). Lung cancer diagnosis from proteomic analysis of preinvasive lesions. Cancer Res, 71, 3009-17.   DOI   ScienceOn
28 Ravenna L, Sale P, Di Vito M, et al (2009). Up-regulation of the inflammatory-reparative phenotype in human prostate carcinoma. The Prostate, 69, 1245-55.   DOI   ScienceOn
29 Sehramm M, Wrobel C, Born I, et al (2011). Equivocal cytology in lung cancer diagnosis: improvement of diagnostic accuracy using adjuvant multicolor FISH, DNA-image cytometry, and quantitative promoter hypermethylation analysis. Cancer Cytopathol, 119, 177-92.   DOI
30 Reed MF, Molloy M, Dalton EL, et al (2004). Survival after resection for lung cancer is the outcome that matters. Am J Surg, 188, 598-602.   DOI   ScienceOn
31 Shinkai T, Saijo N, Tominaga K, et al (1986). Serial plasma carcinoembryonic antigen measurement for monitoring patients with advanced lung cancer during chemotherapy. Cancer, 57, 1318-23.   DOI
32 Spiro SG, Gould MK, Colice GL,et al (2007). Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest, 132, S149-60.   DOI   ScienceOn
33 Wagner PD, Verma M, Srivastava S (2004). Challenges for biomarkers in cancer detection. Ann N Y Acad Sci, 1022, 9-16.   DOI   ScienceOn
34 Willeke F, Assad A, Findeisen P, et al (2005). Overexpression of a member of the pentraxins family (PTX3) in human soft tissue liposarcoma. Eur J Cancer, 42, 2639-46.